Richard Scott Blackley Sells 68,978 Shares of Oscar Health, Inc. (NYSE:OSCR) Stock

Oscar Health, Inc. (NYSE:OSCR) CFO Richard Scott Blackley sold 68,978 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $17.99, for a total value of $1,240,914.22. Following the transaction, the chief financial officer now directly owns 884,213 shares of the company’s stock, valued at $15,906,991.87. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Oscar Health Stock Performance

Oscar Health stock opened at $16.99 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.91 and a quick ratio of 0.91. The company has a market cap of $4.03 billion, a P/E ratio of -42.48, a price-to-earnings-growth ratio of 36.25 and a beta of 1.61. Oscar Health, Inc. has a fifty-two week low of $4.72 and a fifty-two week high of $23.44. The firm’s 50 day simple moving average is $16.98 and its 200-day simple moving average is $17.23.

Oscar Health (NYSE:OSCR) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.04. The firm had revenue of $2.20 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Oscar Health had a net margin of 0.25% and a return on equity of 1.86%. The company’s quarterly revenue was up 44.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.07) EPS. As a group, equities research analysts predict that Oscar Health, Inc. will post 0.01 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on OSCR. Baird R W upgraded Oscar Health to a “strong-buy” rating in a report on Thursday, May 30th. Piper Sandler upped their price target on shares of Oscar Health from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. Wells Fargo & Company lifted their price objective on shares of Oscar Health from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. Bank of America reiterated a “neutral” rating and issued a $21.00 target price (down from $25.00) on shares of Oscar Health in a report on Thursday, May 30th. Finally, Robert W. Baird assumed coverage on shares of Oscar Health in a report on Thursday, May 30th. They set an “outperform” rating and a $28.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Oscar Health presently has an average rating of “Moderate Buy” and a consensus target price of $24.17.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OSCR. Avalon Trust Co purchased a new position in Oscar Health during the 1st quarter valued at about $69,000. Point72 Hong Kong Ltd acquired a new stake in shares of Oscar Health during the second quarter worth approximately $78,000. Quest Partners LLC purchased a new position in Oscar Health during the second quarter valued at approximately $93,000. Amalgamated Bank increased its stake in Oscar Health by 27.7% in the 2nd quarter. Amalgamated Bank now owns 6,727 shares of the company’s stock valued at $106,000 after buying an additional 1,458 shares during the period. Finally, Prevail Innovative Wealth Advisors LLC purchased a new stake in Oscar Health in the 4th quarter worth approximately $92,000. 75.70% of the stock is owned by institutional investors and hedge funds.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.